{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-008420","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.232173+00:00","generated_at":"2026-06-25T17:49:43.425542+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Altimmune Q1 net loss $19.4M ($0.44/share); cash $180.0M; key pemvidutide data readouts Q3/Q4 2022","bullets":["Net loss of $19.4M ($0.44 per share) vs $14.9M ($0.38) in Q1 2021; R&D expense $15.1M.","Cash, cash equivalents and restricted cash totaled $180.0M at March 31, 2022.","Pemvidutide Phase 2 MOMENTUM obesity trial enrolling ~320 subjects; interim 24-week data expected Q4 2022.","Phase 1b NAFLD trial enrollment completed; 12-week liver fat and weight loss data expected Q3 2022.","HepTcell Phase 2 chronic hepatitis B trial continuing; data readout expected H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-008420","json":"https://secwatch.observer/filing/0001558370-22-008420.json","markdown":"https://secwatch.observer/filing/0001558370-22-008420.md","text":"https://secwatch.observer/filing/0001558370-22-008420.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000155837022008420/0001558370-22-008420-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000155837022008420/alt-20220512x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T17:49:43.425542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}